These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15359941)

  • 1. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 3. Should we be using activated protein C to treat severe sepsis?
    Eve RL; Duffy MR
    Br J Hosp Med (Lond); 2009 Aug; 70(8):484. PubMed ID: 19684544
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sepsis in the surgical setting: indication for activated C protein].
    Payen DM; Matéo J
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():40-2. PubMed ID: 15359942
    [No Abstract]   [Full Text] [Related]  

  • 5. Activated protein C for sepsis.
    Mackenzie A
    N Engl J Med; 2010 Mar; 362(12):1150-1; author reply 1151. PubMed ID: 20335597
    [No Abstract]   [Full Text] [Related]  

  • 6. [PROWESS: description and key results].
    Vallet B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():12-5. PubMed ID: 15359933
    [No Abstract]   [Full Text] [Related]  

  • 7. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

  • 9. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 10. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.
    Barie PS; Hydo LJ; Shou J; Eachempati SR
    Surg Infect (Larchmt); 2006; 7 Suppl 2():S77-80. PubMed ID: 16895513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. For sepsis, the drugs don't work.
    Lancet Infect Dis; 2012 Feb; 12(2):89. PubMed ID: 22281132
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.
    de Pont AC; Bakx R; Boermeester MA; Schultz MJ
    Surgery; 2007 Jun; 141(6):828-9. PubMed ID: 17560262
    [No Abstract]   [Full Text] [Related]  

  • 14. Stopping trials early for benefit--not so fast!
    Faust AC; Chung T; Feldman M
    Ann Pharmacother; 2012 Nov; 46(11):1564-7. PubMed ID: 23136354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 16. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.
    Carlet J
    Intensive Care Med; 2004 May; 30(5):994; author reply 995. PubMed ID: 15083270
    [No Abstract]   [Full Text] [Related]  

  • 17. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.